The effect of perinatal exposures on the infant: Antidepressants and depression

Best Practice and Research: Clinical Obstetrics and Gynaecology

Volumn 28, Issue 1, 2014, Pages 37-48

  Hanley, Gillian E ^a,b   Oberlander, Tim F ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Infant outcomes; Prenatal maternal depression; Serotonin reuptake inhibitors

Indexed keywords

ANTIDEPRESSANT AGENT; HYDROCORTISONE; NORADRENALIN; PAROXETINE; SEROTONIN UPTAKE INHIBITOR;

ADAPTATION SYNDROME; ARTICLE; BRAIN DEVELOPMENT; CHILD DEVELOPMENT; CONGENITAL HEART MALFORMATION; DRUG USE; GENETIC VARIABILITY; HUMAN; LOW BIRTH WEIGHT; MENTAL HEALTH; PERSISTENT PULMONARY HYPERTENSION; PREMATURITY; PRENATAL EXPOSURE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; PUERPERAL DEPRESSION; SMALL FOR DATE INFANT; SOCIAL STATUS; SPONTANEOUS ABORTION;

INFANT OUTCOMES; PRENATAL MATERNAL DEPRESSION; SEROTONIN REUPTAKE INHIBITORS;

ANTIDEPRESSIVE AGENTS; ANXIETY; CHILD BEHAVIOR DISORDERS; DEPRESSION; FEMALE; GENERAL ADAPTATION SYNDROME; HEART DEFECTS, CONGENITAL; HUMANS; INFANT, NEWBORN; PERSISTENT FETAL CIRCULATION SYNDROME; PREGNANCY; PREGNANCY COMPLICATIONS; PRENATAL EXPOSURE DELAYED EFFECTS; SEROTONIN UPTAKE INHIBITORS;

EID: 84891632433     PISSN: 15216934     EISSN: 15321932     Source Type: Journal    
DOI: 10.1016/j.bpobgyn.2013.09.001     Document Type: Article

References (109)

1. Cooper WO, Willy ME, Pont SJ, et al. Increasing use of antidepressants in pregnancy. Am J Obstet Gynecol 2007;196: 544.e1-5.
2. Oberlander TF, Warburton W, Misri S, et al. Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data. Arch Gen Psychiatry 2006;63:898-906.
3. Daw JR, Mintzes B, Law MR, et al. Prescription drug use in pregnancy: a retrospective, population-based study in British Columbia, Canada (2001-2006). Clin Ther 2011;34:239-49.
4. Alwan S, Friedman JM. Safety of selective serotonin reuptake inhibitors in pregnancy. CNS Drugs 2009;23:493-509.
5. Hemels MEH, Einarson A, Koren G, et al. Antidepressant use during pregnancy and the rates of spontaneous abortions: a meta-analysis. Ann Pharmacother 2005;39:803-9.
6. Koren G, Nordeng H. Antidepressant use during pregnancy: the benefit-risk ratio.AmJ Obstet Gynecol 2012;207:157-63.
7. Wilson KL, Zelig CM, Harvey JP, et al. Persistent pulmonary hypertension of the newborn is associated with mode of delivery and not with maternal use of selective serotonin reuptake inhibitors. Am J Perinatol 2011;28:19.
8. Byatt N, Deligiannidis KM, Freeman MP. Antidepressant use in pregnancy: a critical review focused on risks and controversies. Acta Psychiatr Scand 2013;127:94-114.
9. Glover V. Maternal stress or anxiety during pregnancy and the development of the baby Pract Midwife 1999;2:20-2.
10. Andersson L, Sundström-Poromaa I, Wulff M, et al. Implications of antenatal depression and anxiety for obstetric outcome. Obstet Gynecol 2004;104:467-76.
11. Lindgren K. Relationships among maternal-fetal attachment, prenatal depression, and health practices in pregnancy. Res Nurs Health 2001;24:203-17.
12. Kim J, Riggs WK, Misri S, et al. Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feeding. Br J Clin Pharmacol 2006;61:155-63.
13. Homberg JR, Schubert D, Gaspar P. New perspectives on the neurodevelopmental effects of SSRIs. Trends Pharmacol Sci 2010;31:60-5.
14. Gaspar P, Cases O, Maroteaus L. The developmental role of serotonin: news from mouse molecular genetics. Nat Rev Neurosci 2003;4:1002-12.
15. Oberlander T, Gingrich J, Ansorge M. Sustained neurobehavioral effects of exposure to SSRI antidepressants during development: molecular to clinical evidence. Clin Pharm Ther 2009;86:672-7.
16. Einarson A, Fatoye B, Sarkar M, et al. Pregnancy outcome following gestational exposure to venlafaxine: a multicenter prospective controlled study. Am J Psychiatry 2001;158:1728-30.
17. Malm H, Klaukka T, Neuvonen PJ. Risks associated with selective serotonin reuptake inhibitors in pregnancy. Obstet Gynecol 2005;106:1289-96.
18. Chung TKH, Lau TK, Yip ASK. Antepartum depressive symptomatology is associated with adverse obstetric and neonatal outcomes. Psychosom Med 2001;63:830-4.
19. Field T, Diego M, Hernandez-Reif M, et al. Pregnancy anxiety and comorbid depression and anger: effects on the fetus and neonate. Depress Anxiety 2003;17:140-51.
20. Grote NK, Bridge JA, Gavin AR, et al. A meta-analysis of depression during pregnancy and the risk of preterm birth, low birth weight, and intrauterine growth restriction. Arch Gen Psychiatry 2010;67:1012-24.
21. Dayan J, Creveuil C, Herlicoviez M, et al. Role of anxiety and depression in the onset of spontaneous preterm labor. Am J Epidemiol 2002;155:293-301.
22. Hoffman S, Hatch MC. Depressive symptomatology during pregnancy: evidence for an association with decreased fetal growth in pregnancies of lower social class women. Health Psychol 2000;19:535-43.
23. Orr ST, James SA, Blackmore PC. Maternal prenatal depressive symptoms and spontaneous preterm births among African-American women in Baltimore, Maryland. Am J Epidemiol 2002;156:797-802.
24. Steer RA, Scholl TO, Hediger ML, et al. Self-reported depression and negative pregnancy outcomes. J Clin Epidemiol 1992;45:1093-9.
25. Teixera JA, Fisk N, Glover V. Association between maternal anxiety in pregnancy and increased uterine artery resistance. BMJ 1999;318:153-7.
26. Glover V. Annual research review: prenatal stress and the origins of psychopathology: an evolutionary perspective. J Child Psychol Psyc 2011;52:356-67.
27. Mendelson T, DiPietro JA, Costigan KA, et al. Associations of maternal psychological factors with umbilical and uterine blood flow. J Psychosom Obstet Gynaecol 2011;32:3-9.
28. Abrams B, Selvin S. Maternal weight gain pattern and birth weight. Obstet Gynecol 1995;86:163-9.
29. Field T, Diego MA, Dieter J, et al. Depressed withdrawn and intrusive mothers' effects on their fetuses and neonates. Infant Behav Dev 2001;24:27-39.
30. Lundy B, Field Jeffrey T. Newborns of mothers with depressive symptoms are less expressive. Infant Behav Dev 1996; 19:419-24.
31. Misri S, Oberlander TF, Fairbrother N, et al. Relation between prenatal maternal mood and anxiety and neonatal health. Can J Psychiat 2004;49:684-9.
32. Van den Bergh BRG, Marcoen A. High antenatal maternal anxiety is related to ADHD symptoms, externalizing problems, and anxiety in 8-and 9-year olds. Child Dev 2004;75:1085-97.
33. Zuckerman B, Bauchner H, Parker S, et al. Maternal depressive symptoms during pregnancy, and newborn irritability. J Dev Behav Pediatr 1990;11:190-4.
34. Allister L, Lester BM, Carr S, et al. The effects of maternal depression on fetal heart rate response to vibroacoustic stimulation. Dev Neuropsychol 2001;20:639-51.
35. Monk C, Fifer WP, Myers MM, et al. Maternal stress responses and anxiety during pregnancy: effects on fetal heart rate. Dev Psychobiol 2000;36:67-77.
36. Talge NM, Neal C, Glover V. Antenatal maternal stress and long-term effects on child neurodevelopment: how and why? J Child Psychol Psyc 2007;48:245-61.
37. Oberlander TF, Wisner KL. A tale of 2s: optimizing maternal-child health in the context of antenatal maternal depression and antidepressant use. Can J Psychiatry 2012;57:519-22.
38. Dietz P, Williams S, Callaghan W, et al. Clinically identified maternal depression before, during, and after pregnancies ending in live births. Am J Psychiatry 2007;164:1515-20.
39. Andersson L, Sundström-Poromaa I, Wulff M, et al. Neonatal outcome following maternal antenatal depression and anxiety: a population-based study. Am J Epidemiol 2004;159:872-81.
40. Berle J, Mykletun A, Daltveit A, et al. Neonatal outcomes in offspring of women with anxiety and depression during pregnancy. Arch Women Ment Health 2005;8:181-9.
41. Larsson C, Sydsjö G, Josefsson A. Health, sociodemographic data, and pregnancy outcome in women with antepartum depressive symptoms. Obstet Gynecol 2004;104:459-66.
42. Perkin M, Bland J, Peacock J, et al. The effect of anxiety and depression during pregnancy on obstetric complications. BJOG 1993;100:629-34.
43. Wu J, Viguera A, Riley L, et al. Mood disturbance in pregnancy and the mode of delivery. Am J Obstet Gynecol 2002; 187:864-7.
44. Alder J, Fink N, Bitzer J, et al. Depression and anxiety during pregnancy: a risk factor for obstetric, fetal and neonatal outcome? A critical review of the literature. J Matern Fetal Neonatal Med 2007;20:189-209.
45. Kyrklund-Blomberg NB, Cnattingius S. Preterm birth and maternal smoking: risks related to gestational age and onset of delivery. Am J Obstet Gynecol 1998;179:1051-5.
46. Kozhimannil KB, Pereira MA, Harlow BL. Association between diabetes and perinatal depression among low-income mothers. JAMA 2009;301:842-7.
47. Haelterman E, Breart G, Paris-Liado J, et al. Effect of uncomplicated chronic hypertension on the risk of small-forgestational age birth. Am J Epidemiol 1997;145:689-95.
48. Kurki T, Hiilesmaa V, Raitasalo R, et al. Depression and anxiety in early pregnancy and risk for preeclampsia. Obstet Gynecol 2000;95:487-90.
49. Kelly RH, Russo J, Holt VL, et al. Psychiatric and substance use disorders as risk factors for low birth weight and preterm delivery. Obstet Gynecol 2002;100:297-304.
50. Yonkers KA, Gotman N, Smith MV, et al. Does antidepressant use attenuate the risk of a major depressive episode in pregnancy? Epidemiology 2011;22:848-54.
51. Freeman MP. Complementary and alternative medicine for perinatal depression. J Affect Disord 2009;112:1-10.
52. Bérard A, Ramos É, Rey É, et al. First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage. Birth Defects Res B Dev Reprod Toxicol 2007;80:18-27.
53. Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn. N Engl J Med 2006;354:579-87.
54. Nakhai-Pour HR, Broy P, Berard A. Use of antidepressants during pregnancy and the risk of spontaneous abortion. Can Med Assoc J 2010;182:1031-7.
55. Oberlander TF, Warburton W, Misri S, et al. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data. Birth Defects Res B Dev Reprod Toxicol 2008;83:68-76.
56. Pedersen LH, Henriksen TB, Vestergaard M, et al. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 2009;339:b3569-75.
57. Wurst KE, Poole C, Ephross SA, et al. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: a meta-analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol 2010;88: 159-70.
58. Casper RC, Fleisher BE, Lee-Ancajas JC, et al. Follow-up of children of depressed mothers exposed or not exposed to antidepressant drugs during pregnancy. J Pediatr 2003;142:402-7.
59. Mortensen J, Olsen J, Larsen H, et al. Psychomotor development in children exposed in utero to benzodiazepines, antidepressants, neuroleptics, and anti-epileptics. Eur J Epidemiol 2003;18:769-71.
60. Pedersen LH, Henriksen TB, Olsen J. Fetal exposure to antidepressants and normal milestone development at 6 and 19 months of age. Pediatrics 2010;125:e600-8.
61. Oberlander TF, Eckstein G. Prolonged prenatal psychotropic medication exposure alters neonatal acute pain response. Pediatr Res 2002;51:443-53.
62. Croen LA, Grether JK, Yoshida CK, et al. Antidepressant use during pregnancy and childhood autism spectrum disorders. Arch Gen Psychiatry 2011;68:1104-12.
63. Nulman I, Rovet J, Stewart DE, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997;336:258-62.
64. Nulman I, Rovet J, Stewart DE, et al. Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study. Am J Psychiatry 2002;159:1889-95.
65. Chambers CD, Johnson KA, Dick LM, et al. Birth outcomes in pregnant women taking fluoxetine. N Engl J Med 1996; 335:1010-5.
66. Levinson-Castiel R, Merlob P, Linder N, et al. Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants. Arch Pediatr Adolesc Med 2006;160:173.
67. Moses-Kolko EL, Bogen D, Perel J, et al. Neonatal signs after late in utero exposure to serotonin reuptake inhibitors. JAMA 2005;293:2372-83.
68. Wisner KL, Sit DKY, Hanusa BH, et al. Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes. Am J Psychiatry 2009;166:557.
69. Davis RL, Rubanowice D, McPhillips H, et al. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy. Pharmacoepidemiol Drug Saf 2007;16:1086-94.
70. Diav-Citrin O, Shechtman S, Weinbaum D, et al. Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study. Br J Clin Pharmacol 2008;66:695-705.
71. Costei AM, Kozer E, Ho T, et al. Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 2002;156:1129-32.
72. Laine K, Heikkinen T, Ekblad U, et al. Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactin concentrations. Arch Gen Psychiatry 2003;60:720-6.
73. Kallen B. Neonate characteristics after maternal use of antidepressants in late pregnancy. Arch Pediatr Adolesc Med 2004;158:312-6.
74. Warner CH, Bobo W, Warner C, et al. Antidepressant discontinuation syndrome. Am Fam Physician 2006;74:449.
75. Oberlander TF, Misri S, Fitzgerald CE, et al. Pharmacologic factors associated with transient neonatal symptoms following prenatal psychotropic medication exposure. J Clin Psychiatry 2004;65:230-7.
76. Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol 1996;16:356.
77. Pawluski JL, Galea LAM, Brain U, et al. Neonatal S100B protein levels after prenatal exposure to selective serotonin reuptake inhibitors. Pediatrics 2009;124:e662-70.
78. Davidson S, Prokonov D, Taler M, et al. Effect of exposure to selective serotonin reuptake inhibitors in utero on fetal growth: potential role for the IGF-I and HPA axes. Pediatr Res 2009;65:236-41.
79. Hilli J, Heikkinen T, Rontu R, et al. MAO-A and COMT genotypes as possible regulators of perinatal serotonergic symptoms after in utero exposure to SSRIs. Eur Neuropsychopharmacol 2009;19:363-70.
80. Oberlander TF, Reebye P, Misri S, et al. Externalizing and attentional behaviors in children of depressed mothers treated with a selective serotonin reuptake inhibitor antidepressant during pregnancy. Arch Pediatr Adolesc Med 2007;161:22.
81. Klinger G, Frankenthal D, Merlob P, et al. Long-term outcome following selective serotonin reuptake inhibitor induced neonatal abstinence syndrome. J Perinatol 2011;31:615-20.
82. Pollock BG, Ferrell RE, Mulsant BH, et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000;23:587-90.
83. Oberlander T, Bonaguro R, Misri S, et al. Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications. Mol Psychiatry 2007; 13:65-73.
84. Cohen LS, Heller VL, Bailey JW, et al. Birth outcomes following prenatal exposure to fluoxetine. Biol Psychiatry 2000; 48:996-1000.
85. Shea A, Oberlander TF, Rurak D. Fetal serotonin reuptake inhibitor antidepressant exposure: maternal and fetal factors. Can J Psychiatry 2012;57:523-9.
86. Austin MP. To treat or not to treat: maternal depression, SSRI use in pregnancy and adverse neonatal effects. Psychol Med 2006;36:1663-70.
87. Klinger G, Merlob M. Selective serotonin reuptake inhibitor induced neonatal abstinence syndrome. Isr J Psychiatry Relat Sci 2008;45:107-13.
88. Cole JA, Ephross SA, Cosmatos IS, et al. Paroxetine in the first trimester and the prevalence of congenital malformations. Pharmacoepidemiol Drug Saf 2007;16:1075-85.
89. Källén BAJ, Otterblad Olausson P. Maternal use of selective serotonin reuptake inhibitors in early pregnancy and infant congenital malformations. Birth Defects Res A Clin Mol Teratol 2007;79:301-8.
90. Wogelius P, Nørgaard M, Gislum M, et al. Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations. Epidemiology 2006;17:701.
91. Pastuszak A, Schick-Boschetto B, Zuber C, et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993;269:2246.
92. Kulin NA, Pastuszak A, Sage SR, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors. JAMA 1998;279:609-10.
93. Jimenez-Solem E, Andersen JT, Petersen M, et al. Exposure to selective serotonin reuptake inhibitors and the risk of congenital malformations: a nationwide cohort study. BMJ Open 2012;2(3).
94. Simoncelli M, Martin BZ, Berard A. Antidepressant use during pregnancy: a critical systematic review of the literature. Curr Drug Saf 2010;5:153-70.
95. Riggin L, Frankel Z, Moretti M, et al. The fetal safety of fluoxetine: a systematic review and meta-analysis. J Obstet Gynaecol Can 2013;35:362-9.
96. Koppel RI, Druschel CM, Carter T, et al. Effectiveness of pulse oximetry screening for congenital heart disease in asymptomatic newborns. Pediatrics 2003;111:451-5.
97. Druschel C, Hughes JP, Olsen C. Mortality among infants with congenital malformations, New York State, 1983 to 1988. Public Health Rep 1996;111:359.
98. Riede FT, Wörner C, Dähnert I, et al. Effectiveness of neonatal pulse oximetry screening for detection of critical congenital heart disease in daily clinical routinedresults from a prospective multicenter study. Eur J Pediatr 2010;169: 975-81.
99. Thangaratinam S, Brown K, Zamora J, et al. Pulse oximetry screening for critical congenital heart defects in asymptomatic newborn babies: a systematic review and meta-analysis. Lancet 2012;379:2459-64.
100. Lakshminrusimha S, Steinhom RH. Pulmonary vascular biology during neonatal transition. Clin Perinatol 1999;26: 601-19.
101. Konduri GG, Kim UO. Advances in the diagnosis and management of persistent pulmonary hypertension of the newborn. Pediatr Clin North Am 2009;56:579-600.
102. Källén B, Olausson PO. Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2008;17:801-6.
103. Reis M, Källén B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010;40:1723-33.
104. Kieler H, Artama M, Engeland A, et al. Selective serotonin reuptake inhibitors during pregnancy and risk of persistent pulmonary hypertension in the newborn: population based cohort study from the five Nordic countries. BMJ 2012; 344:d8012.
105. Andrade SE, McPhillips H, Loren D, et al. Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn. Pharmacoepidemiol Drug Saf 2009;18:246-52.
106. Jong GW, Einarson T, Koren G, et al. Antidepressant use in pregnancy and persistent pulmonary hypertension of the newborn (PPHN): a systematic review. Reprod Toxicol 2012;34:293-7.
107. Carlo WA. The high-risk infant. In: Kliegman, et al., editors. Nelson textbook of pediatrics. 19th ed. Philadelphia, PA: Elsevier Inc; 2011. p. 552-64.
108. Oishi M, Nishida H, Kabe K, et al. Monitoring neonatal peripheral circulation by electrocardiogram-to-oximeter pulse velocity. Pediatr Res 1993;33:653-7.
109. Yonkers KA, Wisner KL, Stewart DE, et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. Gen Hosp Psychiatry 2009;31:403.